Back to User profile » Professor Davide Croce
Papers published by Professor Davide Croce:
Change and Innovation in Healthcare: Findings from Literature
Milella F, Minelli EA, Strozzi F, Croce D
ClinicoEconomics and Outcomes Research 2021, 13:395-408
Published Date: 19 May 2021
Overcoming Barriers to the Effective Management of Severe Asthma in Italy
Paggiaro P, Barbaglia S, Centanni S, Croce D, Desideri E, Giustini S, Micheletto C, Musarra A, Scichilone N, Trama U, Zedda MT, Canonica GW
Journal of Asthma and Allergy 2021, 14:481-491
Published Date: 10 May 2021
Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation
Restelli U, Croce D, Bonizzoni E, Marzanatti M, Andreini A, Sorio M, Tecchio C, Barison E, Benedetti F
Journal of Blood Medicine 2020, 11:123-130
Published Date: 2 April 2020
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]
Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A
Journal of Blood Medicine 2019, 10:69-70
Published Date: 8 February 2019
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A
Journal of Blood Medicine 2019, 10:21-27
Published Date: 27 December 2018
A comparison between WHODAS 2.0 and Modified Barthel Index: which tool is more suitable for assessing the disability and the recovery rate in orthopedic rehabilitation?
Galli T, Mirata P, Foglia E, Croce D, Porazzi E, Ferrario L, Ricci E, Garagiola E, Pagani R, Banfi G
ClinicoEconomics and Outcomes Research 2018, 10:301-307
Published Date: 5 June 2018
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D
Therapeutics and Clinical Risk Management 2017, 13:787-797
Published Date: 29 June 2017
Economic and organizational sustainability of a negative-pressure portable device for the prevention of surgical-site complications
Foglia E, Ferrario L, Garagiola E, Signoriello G, Pellino G, Croce D, Canonico S
ClinicoEconomics and Outcomes Research 2017, 9:343-351
Published Date: 12 June 2017
Financial and feasibility implications of the treatment of hepatitis C virus in Italy: scenarios and perspectives
Croce D, Bonfanti M, Restelli U
ClinicoEconomics and Outcomes Research 2016, 8:377-385
Published Date: 8 August 2016
Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service
Restelli U, Andreoni M, Antinori A, Bonfanti M, Di Perri G, Galli M, Lazzarin A, Rizzardini G, Croce D
ClinicoEconomics and Outcomes Research 2014, 6:409-414
Published Date: 23 September 2014
Cost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile?
Rizzardini G, Restelli U, Bonfanti P, Porazzi E, Ricci E, Foglia E, Carenzi L, Croce D
ClinicoEconomics and Outcomes Research 2012, 4:245-252
Published Date: 5 September 2012